Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06527404 · ClinicalTrials.gov registry record · Phase 3
A Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab in Prurigo Nodularis
A Phase 3 study of Prurigo Nodularis, sponsored by Amgen.
- Active
- Registry status
- Phase 3
- Development phase
- 469
- Enrollment target
- 20
- Study locations
NCT06527404 is a Phase 3 study of Prurigo Nodularis that is active but no longer recruiting, run by Amgen. The registered enrollment target is 469 participants, above the 196-participant average among 14 other Prurigo Nodularis trials with a reported enrollment target (139% higher). The trial reports 20 study locations across 9 states.
The verdict
NCT06527404, a Phase 3 study of Prurigo Nodularis, is active but no longer recruiting, sponsored by Amgen.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 469 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main objective of the study will be to evaluate the efficacy of rocatinlimab compared with placebo at week 24 on the patient-reported outcome (PRO) measure of pruritus and overall clinical assessment score (US only).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Rocatinlimab
Study Locations (20)
Florida
- Direct Helpers Research Center - Hialeah
- Southern Clinical Research - Miami
- University of Miami Hospital - Miami
- Miami Dermatology and Laser Institute - Miami
- Wellness Clinical Research - Miami Lakes
- Clinical Research Trials of Florida Inc - Tampa
- Olympian Clinical Research - Tampa - Tampa
California
- First OC Dermatology - Fountain Valley
- Los Angeles Universal Research Center - Los Angeles
- Paradigm Clinical Research Center Inc - San Diego
- Wolverine Clinical Trials - Santa Ana
Ohio
- Optima Research - Boardman
- University Hospitals Cleveland Medical Center - Cleveland
- Wright State Physicians - Fairborn
Alabama
- University of Alabama at Birmingham - Birmingham
Georgia
- Emory University - Atlanta
Illinois
- Endeavor Health Clinical Trials Center - Skokie
Indiana
- The Indiana Clinical Trials Center PC - Plainfield
Michigan
- Revival Research Institute, LLC - Troy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 469 participants |
| Start Date | 2024-07-18 |
| Est. Completion | 2027-01-17 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06527404
The ClinicalTrials.gov registry entry for NCT06527404 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 469 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 196-participant average among 14 other Prurigo Nodularis trials with a reported enrollment target (139% higher). The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Prurigo Nodularis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06527404 reports 20 study locations spanning 9 distinct geographic areas - top geographies include Florida, California, Ohio.
Frequently Asked Questions
What is clinical trial NCT06527404 about?
NCT06527404 is a clinical study titled "A Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab in Prurigo Nodularis". The main objective of the study will be to evaluate the efficacy of rocatinlimab compared with placebo at week 24 on the patient-reported outcome (PRO) measure of pruritus and overall clinical assessment score (US only).
What is the current status of trial NCT06527404?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 469 participants. The study started on 2024-07-18. Estimated completion is 2027-01-17.
What conditions does trial NCT06527404 study?
This clinical trial studies the following conditions: Prurigo Nodularis.
What interventions are being tested in trial NCT06527404?
The interventions under investigation include: Placebo (DRUG), Rocatinlimab (DRUG).
Who is sponsoring clinical trial NCT06527404?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06527404 being conducted?
This trial has 20 study locations across Alabama, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prurigo Nodularis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2)
RECRUITING · Phase 3
-
A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥6 Months to <18 Years of Age With Prurigo Nodularis
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1)
RECRUITING · Phase 3
-
A Long-term Study of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)
COMPLETED · Phase 3
-
A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Prurigo Nodularis (PN)
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.